T he lung has been considered the most common primary site for small cell lung cancer (SCLC) since Barnard first described it in 1926. Nevertheless, primary small cell gastrointestinal carcinoma accounted for 0.1 to 1.0% of malignant gastrointestinal tumors, most of which were derived from the esophagus. Small cell esophageal carcinoma (SCEC) was first described in 1952, accounting for 0.4 to 2.7% of all esophageal carcinomas [1] [2] [3] ; it is a rare and aggressive carcinoma, characterized by early dissemination. Surgical resection, radiation therapy, and multiagent chemotherapy have been used alone and in combination. The prognosis for SCEC remains poor, and there is no standard treatment at present. 4 -12 In this study, we retrospectively analyzed 126 cases of SCEC treated at our institution between May 1985 and June 2005, to identify prognostic factors, and we discuss the principles of treatment.
PATIENTS AND METHODS
Between May 1985 and June 2005, a total of 126 SCEC cases were treated at the Cancer Hospital of Peking Union Medical College and the Chinese Academy of Medical Sciences. The clinical records of these patients were analyzed retrospectively. The study was approved by the Independent Ethics Committee of the Cancer Hospital and Chinese Academy of Medical Sciences.
Patient Selection and Staging
All patients were questioned about their medical history and underwent physical examinations. Chest radiograph, barium meal, Doppler ultrasound examination of the abdomen, complete blood count, blood biochemistry analyses, and liver and renal function evaluations were also performed. For cases amenable to surgery, electrocardiograms and lung function tests were also performed. Unless clinically indicated, brain magnetic resonance imaging and radioactive isotope bone scans were not performed. The World Health Organization histologic criteria for small cell carcinoma were adopted. All patients were diagnosed histologically before treatment. Most of the postoperative specimens (70 cases) were rereviewed in the study. All patients were staged as limited disease (LD) or extensive disease (ED) according to the Veterans' Administration Lung Study Group staging system. Lesions confined to the esophagus and adjacent organs with or without regional lymph node involvement were classified as LD, whereas lesions spreading beyond locoregional boundaries were classified as ED. The TNM system for esophageal carcinoma (6th edition, American Joint Committee on Cancer) was also used for those who underwent esophagectomies.
Patient Characteristics
Between May 1985 and June 2005, 126 cases of SCEC were diagnosed histologically at our institution, accounting for 1.2% of esophageal carcinomas treated in the same period. The patients had a median age of 58 years, with a male to female ratio of 3.7:1. There were 119 cases with a Karnofsky score more than or equal to 80. Complete blood counts, blood biochemistry analyses, and liver and renal function tests were within normal ranges for all except one patient, who had moderate anemia before treatment. The primary lesions were most often found in the middle third of the thoracic esophagus and had a median length of 5.5 cm. According to the barium meal, 55 cases were classified as mushroom-or intraluminal-type. There were 36 cases of combined types in the resected cases, who had preoperatively been confused with squamous cell carcinoma. Of the total cases, 85 were staged as LD and 41 were staged as ED (with hematogenous metastases in 10 cases).
Of 
Treatment
Of the 126 cases, 84 received surgical resection, 63 received radiotherapy, and 88 received chemotherapy. Esophagectomy (S) was performed alone in 22 cases. Radiotherapy (R) was delivered alone in 12 cases, and chemotherapy (C) was given alone in seven cases. Four cases were treated with S ϩ R; 34 cases were treated with S ϩ C, including two cases of preoperative chemotherapy; 24 cases were treated with S ϩ C ϩ R; and 23 cases were treated with R ϩ C. Of the 23 cases treated with R ϩ C, 10 cases received chemotherapy followed by sequential radiotherapy (including two cases of salvage radiotherapy), 11 cases received radiotherapy followed by sequential chemotherapy, and two cases received concurrent chemoradiotherapy. The 38 cases treated with R or S Ϯ R were defined as the local therapy group, and the 81 cases treated with S ϩ C Ϯ R or R ϩ C were defined as the systemic therapy group. Chemotherapy started more than 2 months after local therapy was defined as delayed chemotherapy. There were only 14 cases of LD who received chemotherapy first. Fourteen cases received delayed chemotherapy (nine in the S ϩ C Ϯ R group, five in the R ϩ C group). In the nonresection group, there were more cases of age more than or equal to 70 years, more cases located in the upper third of the thoracic esophagus, and more cases with ED. Nevertheless, there was no difference in any of these factors between the chemotherapy and nonchemotherapy groups.
Surgery
There were five cases of explorative resection, and 79 cases were treated by esophagectomy with two-field lymph node dissection (the mediastinal and perigastric lymph nodes), including 64 cases of R 0 resection, 3 cases of R 1 resection, and 12 cases of R 2 resection.
Radiotherapy
Radiation was delivered by 6 or 8 MV photons, with a conventional fraction (spinal cord dose, Յ40 Gy). A threedimensional conformal technique was used in only three cases. Eight cases received adjuvant radiotherapy (preoperative radiotherapy at a dose of 40 Gy in three cases). Twenty cases received salvage radiotherapy. The target volume in 58 cases covered the primary lesion (at least 3 cm superiorly and inferiorly and 1.5-2 cm bilaterally from the esophageal lesion) or the tumor bed with regional lymph nodes. The target volume in five cases receiving postoperative salvage radiotherapy included only the superclavicular fossa. Fifty-two cases received a dose more than or equal to 50 Gy, eight received a dose less than or equal to 40 Gy (four cases, Ͻ40 Gy), and the doses in five cases were unknown. 
Chemotherapy
Sixty-seven cases received planned chemotherapy. Fourteen cases received delayed chemotherapy in the systemic therapy group. Three cases underwent single-agent chemotherapy (capecitabine in one case and etoposide in two), and 85 cases received combined chemotherapy (2-4 drugs). Regimens evolved from cyclophosphamide plus vincristine plus mitomycin or not, plus etoposide (COMP or COP) to cyclophosphamide plus adriamycin or epirubicin plus vincas or etoposide (CAO or CAE), and further to cisplatin or carboplatin plus etoposide (PE or CE); some patients received alternating regimens. Forty-nine patients received platinum-based regimens. The regimens in seven cases were unknown (two cases in the S ϩ C group, one case in the S ϩ C ϩ R group, three cases in the R ϩ C group, and one case in the C group). A median course of six (range, 3-12) rounds of chemotherapy was given.
Statistical Analysis
Survival time was calculated from the start of treatment to the point of death or the last follow-up. The failure sites were classified as locoregional recurrence, or distant lymph node or hematogenous metastasis or both. SPSS 10.0 software was used to analyze prognostic factors by Cox's hazard regression model, with the entry factors of age (Ͻ70 versus Ն70 years), gender, Karnofsky score (Ͻ80 versus Ն80), length of the primary lesion (Յ5.0 versus Ͼ5.0 cm), stage (LD/ED), surgery (yes/no), radiotherapy (yes/no), and chemotherapy (yes/no). The 2 test was used to compare frequencies. The Kaplan-Meier and log-rank methods were used to estimate and compare survival rates. Survival curves were also plotted (two-sided test with p Ͻ 0.05).
RESULTS
By December 2005, through a median follow-up of 13 months, 108 patients had died, 10 were alive, and 8 were lost to follow-up.
The overall median survival time (MST) and 1-, 2-, 3-, and 5-year overall survival (OS) rates (ϮSE) were 12.5 months (95% confidence interval ͓CI͔, 10.3-14.7) and 52.2 Ϯ 4.5%, 25.2 Ϯ 3.9%, 15.9 Ϯ 3.4%, and 12.2 Ϯ 3.0%, respectively ( Figure 1 ). The MST (95% CI) and 1-, 2-, 3-, and 5-year OS (ϮSE) for cases of LD versus ED were 14.0 months (11.4 -16.6) and 62.1 Ϯ 5.3%, 30.8 Ϯ 5.1%, 22.4 Ϯ 4.7%, and 16.8 Ϯ 4.3%, versus 7.0 months (5.7-8.3) and 29.3 Ϯ 7.1%, 13.6 Ϯ 5.5%, 2.7 Ϯ 2.7%, and 0%, respectively (p ϭ 0.0001; Figure 2 ). The MST (95% CI) and 1-, 2-, 3-, and 5-year OS (ϮSE) for cases with a primary lesion length less than or equal to 5.0 cm versus cases with a length more than 5.0 cm were 15.0 months (11.3-18.7) and 67.4 Ϯ 6.1%, 34.1 Ϯ 6.3%, 21.3 Ϯ 5.7%, and 17.1 Ϯ 5.3%, versus 8.0 months (6.0 -10.0) and 33.8 Ϯ 6.0%, 17.2 Ϯ 4.7%, 9.4 Ϯ 3.6%, and 7.8 Ϯ 3.3%, respectively (p ϭ 0.0015; Figure 3) .
The MST of 14.5 months for cases who received chemotherapy was superior to that of 5. 
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borderline longer than that for the R group (p ϭ 0.077); when excluding one patient who might have been at an early-stage case in the R group, there was a statistical difference in the MST between the R ϩ C and R groups (p ϭ 0.033). The difference between the MST of 13.0 months for cases who underwent surgical resection and that of 9.5 months for cases who did not was statistically insignificant (p ϭ 0.16), and there was no difference in the MST between the S ϩ C Ϯ R and R ϩ C groups (p ϭ 0.30; Figure 5 ). The MST of 13.0 months for stage IVa cases in the R ϩ C group was equivalent to that of stage III cases in the S ϩ C Ϯ R group (p ϭ 0.78). There was no statistical difference in the MST between each subgroup with local therapy. The MST for stage I ϩ II cases (29.0 months) was longer than that for stage III ϩ IV cases (3.0 months) in the S ϩ C Ϯ R group (p ϭ 0.0015). The MSTs according to the different treatment groups are listed in Table 2 . Two cases died during surgery. Esophageal perforation occurred in two cases during treatment. One patient died of treatment toxicity in the R ϩ C group. Residual lesions were detected in postoperative specimens for cases who received preoperative radiotherapy or chemotherapy, but the lesions in the irradiated fields were all obviously improved. The response rate of 73.5% (25 of 34 evaluated cases) was high in cases who received chemotherapy. One patient (LD, with a lesion length of 3 cm) reached a complete response after four courses chemotherapy of carboplatin plus etoposide; he died 55.0 months later from a local recurrence with lung metastasis. Twelve cases survived more than 5 years, including three in the S group (two cases in stage I and one in stage IIb), one in the R group (LD, with a lesion length of 2 cm) who received external irradiation with a dose of 50 Gy plus intracavity irradiation (6 Gy, once a week, twice in total), six cases in the S ϩ C group (three cases each in stage IIa and stage IIb), and two cases in the R ϩ C group (one each of LD and ED). The disease progressed with a median time of 3.0 months in the local therapy group (14 cases) and 8.0 months in the systemic therapy group (59 cases).
The first failure sites in 73 cases included locoregional recurrences in 13 cases, locoregional recurrences with distant metastasis in 22 cases, and distant metastasis in 38 cases. Distant metastasis occurred in 16 cases receiving local therapy during treatment or at the first follow-up (1 month after treatment). The patterns of recurrence according to different treatment groups are shown in Table 3 . There was no difference in the frequency of locoregional recurrence between the S ϩ C Ϯ R and R ϩ C groups (p ϭ 0.385). Metastasis was most frequently detected in the liver, and distant lymph node metastasis was next most common. Of the seven cases in stage I or II, one died during surgery, and 2 died of an accompanying disease 22.0 months and 127.0 months, respectively, after the operation. In four cases in stage I (submucosal carcinoma), distant metastasis occurred after the operation.
The length of the esophageal lesion (hazard ratio ͓HR͔, 1.80; 95% CI, 1.20 -2.71; p ϭ 0.005), the stage (HR, 1.94; 95% CI, 1.27-2.96; p ϭ 0.002), and chemotherapy (HR, 0.42; 95% CI, 0.28 -0.64; p ϭ 0.000) were identified as independent prognostic factors in a multivariate analysis. For postoperative cases, pathologic TNM stage (HR, 1.64; 95% CI, 1.33-2.02; p ϭ 0.000) and chemotherapy (HR, 0.35; 95% CI, 0.21-0.58; p ϭ 0.000) were independent prognostic factors.
DISCUSSION
The clinical manifestations of small cell carcinoma of the esophagus (SCEC) are similar to those of squamous cell carcinoma of the esophagus (SC). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The differential diagnosis is dependent on histopathologic examination. Bronchoendoscopic examination and a computed tomography scan of the thorax should be performed to rule out SCLC. Because of the small amount of preoperative tissue in the present series, some patients were pathologically diagnosed preoperatively as SC, but postoperatively as SCEC combined with SC. The available diagnostic techniques need to be improved.
Similar to the present results, Casas et al. 6 showed that there were significant differences in the MST between LD and ED, as well as between patients with a tumor size less than or equal to 5 cm and those with a tumor size more than 5 cm. As Madroszyk et al. 11 reported, the TNM stage should be used for SCEC, instead of the length of the primary lesion and the limited-extensive stage in the multivariate analysis for resected cases in the present series, because the postoperative pathologic TNM stage is an independent prognostic factor.
Surgical resection, radiation therapy, and multiagent chemotherapy have been used alone and in combination. Nevertheless, the prognosis for SCEC remains poor, and there is no standard treatment. 4 -5,7,10 -11 The present study found that a few cases in stage I ϩ II might be curable by local therapy alone; SCEC was primarily sensitive to chemotherapy or radiotherapy, but the MST values for local therapy and chemotherapy alone were poor and not significantly different. SCEC is a rare and aggressive carcinoma that is characterized by early dissemination. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Nemoto et al. 8 reported that the frequency of metastasis depended on the stage: 0% (0/3) in stage I, 75% (6/8) in stage II, and 78% (7/9) in stage III and that the MST of patients who received chemotherapy was significantly different from those who did not. Casas et al. 6 reported a significant difference in the MST between patients who received systemic therapy and those who received local therapy and found that chemotherapy was an independent prognostic factor. As Nishimaki et al., 12 reported four cases in stage I (submucosal carcinoma) who received surgical resection alone died of visceral metastasis in the present series. The MST for the systemic therapy group was superior to that of the local therapy group, and the MST for cases who received chemotherapy was longer, even in cases of stage II. In addition, multivariate analysis identified chemotherapy and the stage as major prognostic factors in the present study. Thus, SCEC should be considered a systemic disease, and systemic therapy, based on chemotherapy, should be administered even for early-stage disease. Nevertheless, despite the often high initial response rates, the disease frequently progressed shortly after therapy. The development of appropriate regimens needs further study.
Surgical resection was frequently the first choice in the present series. It has been suggested that surgical resection should be a part of systemic therapy for LD-SCEC. 5,9,12-14 Medgyesy et al. 5 considered that long-term survival was lower after chemoradiotherapy because of fewer pathologically complete responses in combined-type SCEC. It has been reported [13] [14] that several LD-SCEC cases, treated by various adjuvant therapies with surgical resection, achieved longer survival times. Sun et al. 9 stated that cases in stage I ϩ II should be eligible for radical resection as part of systemic therapy for SCEC. In the present study, although there were more cases in ED in the nonresection group, there were no statistical differences in the MST values between the resection and nonresection groups or between the S ϩ C Ϯ R and R ϩ C groups. Given that there were more early stage cases in the surgery group, the longer MST for stage I ϩ II might have contributed to the higher number of long-term survival cases in that group. There was no difference in the frequency of locoregional recurrence between the S ϩ C Ϯ R and R ϩ C groups. Two advanced-stage cases in the R ϩ C group survived more than 5 years. In previous reports, 4 -5,7-8,10,15 13 cases in LD (of 41 cases) were long-term survivors with chemotherapy plus radiotherapy. Thus, durable locoregional disease control may also be achieved in cases who receive radiotherapy. On the other hand, it is difficult for surgeons to dissect superior mediastinal lymph nodes completely; therefore, radiotherapy was a salvage treatment in response to locoregional recurrence for the 13 cases in the S ϩ C ϩ R group. Imperfect resection may lead to delayed or even lost opportunities for chemotherapy. Neither surgery nor radiotherapy was an independent prognostic factor in the present multivariate analysis.
The results from the present study support the view 4,6 -8,10,15 that chemoradiotherapy, which is the standard of care for LD-SCLC, should be the standard of care for LD-SCEC. We also found that the MST for stage IVa cases in the R ϩ C group was equal to that for stage III cases in the S ϩ C Ϯ R group. Durable disease control is known to be rare in cases treated with chemotherapy alone. 4 -5,7,10 -11 In addition, radiotherapy might be more useful in SCEC than in SCLC to maintain normal function of the esophagus for as long as possible. These patients may also benefit from radiotherapy. The optimal target coverage and dose are still unknown. Nemoto et al. 8 indicated that a dose of 60 Gy or higher may be appropriate as a radical dose and that 40 to 50 Gy may be used as a prophylactic dose.
CONCLUSIONS
SCEC is a systemic disease, with stage and chemotherapy as independent prognostic factors. Systemic therapy based on chemotherapy with radiotherapy is recommended.
